Updated July 2026 The Ozempic and GLP-1 gastroparesis lawsuits involve claims that manufacturers of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity, Zepbound, and Saxenda failed to adequately warn patients and doctors about the potential risk of developing gastroparesis (i.e., stomach paralysis or delayed gastric emptying), a serious gastrointestinal injury that can cause persistent nausea, vomiting, abdominal pain, bloating, dehydration, malnutrition, hospitalization, or the need for feeding tubes or other invasive treatment
[cited 2024 Nov 15]
It's great to see the data back up what many have been theorizing for awhile
The platform's materials describe this as providing direct delivery into the bloodstream and note that injectable formulations have generally shown stronger weight loss outcomes in published studies compared to oral delivery methods